Communiqués

02/07 IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares AQ
30/06 MultiBagger MicroCaps IGC, RCT, PBK, HUMA, PRSO Stocks to Watch Now AQ
23/06 IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow AQ
11/06 IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis AQ
09/06 Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts AQ
02/06 IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis AQ
19/05 IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment AQ
15/05 IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference AQ
14/05 Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference PU
28/04 IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase AQ
22/04 IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion AQ
20/04 IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia AQ
14/04 IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout AQ
08/04 Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts AQ
07/04 IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease AQ
30/03 IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness AQ
25/03 New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning AQ
19/03 IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 AQ
18/03 IGC Pharma : Annual Transition Report (Form 10-KT) PU
18/03 IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 AQ
03/02 IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation AQ
10/12 IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” PU
19/08/25 IGC Pharma : FYE2025 Annual Meeting Proxy Card PU
19/08/25 IGC Pharma : Notice & Access 2025 ASM PU
19/08/25 IGC Pharma : DEFA 14A 08-18-25 PU
Aucun résultat pour cette recherche